AveXis, an early-stage biotech developing a gene therapy for spinal muscular atrophy, raised $95 million in an upsized IPO by offering 4.75 million shares at $20, the midpoint of the range of $19 to $21. The company originally planned to offer 4.25 million shares. Existing investors had indicated an interest in buying $30 million on the IPO, which would represent 32% of the deal. AveXis plans to list on the Nasdaq under the symbol AVXS. Goldman Sachs and Jefferies acted as lead managers on the deal.
